{
    "2019-11-15": [
        [
            {
                "time": "2023-10-07",
                "original_text": "Novartis sickle-cell drug gets U.S. FDA approval",
                "features": {
                    "keywords": [
                        "Novartis",
                        "sickle-cell",
                        "drug",
                        "FDA",
                        "approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-07",
                "original_text": "CORRECTED-UPDATE 2-Novartis sickle-cell drug gets U.S. FDA approval",
                "features": {
                    "keywords": [
                        "Novartis",
                        "sickle-cell",
                        "drug",
                        "FDA",
                        "approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-07",
                "original_text": "Drug giant Roche acquires Lexington biotech for $390M",
                "features": {
                    "keywords": [
                        "Roche",
                        "acquires",
                        "Lexington",
                        "biotech",
                        "$390M"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}